At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 73 enrolled
Drug / intervention
Everolimusdrug
Likely dose
Everolimus 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-endocrine Tumors
In Brief
A Phase 2 clinical trial evaluating Everolimus for Advanced and Metastatic Silent Neuro-Endocrine Tumors and 6 related conditions. Completed, enrolled 73 participants across 40 sites in 8 countries.
Detailed Summary
To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced and Metastatic Silent Neuro-Endocrine Tumors, Carcinoma, Neuroendocrine, Non Functioning Neuroendocrine Tumors (NETs), Non Syndromic Neuroendocrine Tumors, Carcinoids, Non Functioning
CountriesFrance, Germany, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartJun 2009
Primary CompletionNov 2016
TodayJul 2026
First PostedJun 3, 2008
Enrollment StartJun 24, 2009
Primary CompletionNov 7, 2016
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 18.1 years ago
Interventions
Everolimusdrug
Everolimus 5 mg tablets were supplied in blister packs